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Summary
Background.  —  Drug-eluting  stents  (DES)  are  more  effective  than  bare-metal  stents  (BMS)  in
small coronary  vessel  disease.  Whether  this  is  true  in  elderly  patients,  it  is  unclear,  as  frailty
and a  high  rate  of  comorbidities  could  increase  the  rate  of  DES-related  complications.
Aims. —  To  assess  procedural  and  long-term  clinical  outcomes  of  elderly  patients  with  small
vessel disease  treated  with  DES  or  BMS.intervention;
Small  vessel  disease
Methods.  —  Consecutive  elderly  patients  (≥  75  years  old)  treated  with  stenting  of  native  small
coronary arteries  (reference  vessel  diameter  and  implanted  stent  <  3  mm)  were  recruited  dur-
ing 2004—2008.  Procedural  and  long-term  clinical  outcomes  were  compared  between  patients
treated with  BMS  and  DES.  Propensity  score-adjusted  logistic  regression  analysis  was  performed
to account  for  potential  selection  bias.
Abbreviations: BMS, bare-metal stents; DAPT, dual antiplatelet therapy; DES, drug-eluting stents; IQR, interquartile range; MACE, major
dverse cardiac events; MLD, minimal lumen diameter; PCI, percutaneous coronary intervention; SD, standard deviation; TVR, target vessel
evascularization.
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Results.  —  Among  293  patients  (175  BMS,  118  DES),  peri-procedural  myocardial  infarction  (12
[7%] vs.  5  [4%];  P  =  0.35)  and  blood  transfusions  (3  [2%]  vs.  0;  P  =  0.08)  were  not  signiﬁ-
cantly different  between  the  BMS  and  DES  groups.  Clinical  follow-up  (96%  of  patients,  median
[interquartile  range]  follow-up  3.5  [2.4]  years)  showed  signiﬁcantly  lower  adjusted  major
adverse cardiac  events  (hazard  ratio  [HR]  0.42,  95%  conﬁdence  interval  [CI]  0.24—0.72;
P =  0.002)  and  target  vessel  revascularization  (TVR)  (HR  0.33,  95%  CI  0.14—0.76;  P  =  0.009)  in
the DES  group.  No  signiﬁcant  differences  were  observed  between  the  groups  in  terms  of  death,
myocardial infarction,  stent  thrombosis  or  bleeding.
Conclusions.  —  In  this  retrospective,  non-randomized  analysis  of  the  treatment  of  small  vessel
disease in  elderly  patients,  DES  were  as  safe  and  more  effective  than  BMS  with  a  signiﬁcant
reduction  in  TVR.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Les  stents  actifs  (SA)  sont  plus  efﬁcaces  que  les  stents  non-actifs  (SNA)  pour  traiter
les lésions  des  petits  vaisseaux  coronaires.  Le  bénéﬁce  des  SA  chez  les  patients  âgés  sont  plus
discutés car  il  s’agit  de  patients  plus  fragiles,  avec  plus  de  comorbidités  et  donc  plus  exposés
aux effets  indésirables.
Objectif.  —  Évaluer  les  procédures  et  le  devenir  à  long-terme  des  patients  âgés  avec  des  lésions
dans les  petits  vaisseaux  traités  par  SA  versus  SNA.
Méthodes.  —  Tous  les  patients  âgés  (≥  75  ans)  avec  des  lésions  primitives  dans  les  petits  vais-
seaux (diamètre  de  référence  ou  stent  <  3  mm)  traités  par  angioplastie  avec  pose  de  stent  ont
été recrutés  entre  2004  et  2008.  Les  procédures  et  le  devenir  à  long-terme  ont  été  comparés
selon le  type  de  stent  implanté.  Une  régression  logistique  et  un  score  de  propensité  ont  été
utilisés pour  s’affranchir  d’éventuels  biais.
Résultats.  — Deux  cent  quatre-vingt-treize  patients  ont  été  inclus  (175  SNA,  118  SA).  Le  nombre
d’infarctus  (12  [7  %]  vs  5  [4  %]  ;  p  =  0,35)  et  de  transfusions  (3  [2  %]  vs  0  ;  p  =  0,08)  en  post-
procédure  n’étaient  pas  différents.  Le  suivi  clinique  (96  %  des  patients,  suivi  moyen  [intervalle
interquartile]  3,5  [2,4]  ans)  a  montré  moins  d’événements  cardiovasculaires  majeurs  (risque
relatif [RR]  0,42,  95%  intervalle  de  conﬁance  [IC]  0,24—0,72  ;  p  =  0,002)  et  moins  de  revascu-
larisation  dans  le  vaisseau  traité  (RR  0,33,  95  %  IC  0,14—0,76  ;  p  =  0,009)  chez  les  patients  avec
SA. Aucune  différence  signiﬁcative  n’a  été  observée  entre  les  groupes  concernant  les  décès,
les infarctus,  les  thromboses  de  stents  et  les  saignements.
Conclusions.  — Les  SA  ne  sont  pas  seulement  plus  sures,  mais  sont  aussi  plus  efﬁcaces  que  les
SNA pour  le  traitement  des  lésions  dans  les  petits  vaisseaux  chez  les  patients  âgés.  Le  bénéﬁce
clinique à  long-terme  était  principalement  lié  à  la  réduction  de  la  revascularisation  dans  les
vaisseaux  traités  avec  les  SA.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Elderly  patients  are  increasingly  being  referred  for
percutaneous  coronary  intervention  (PCI).  Yet,  due  to
their  increased  frailty  and  higher  rate  of  comorbidi-
ties  [1—3],  they  are  commonly  considered  to  be  at
high  risk  of  PCI-related  complications  and  therefore
suboptimally  treated  compared  with  younger  patients
[4—6].  Drug-eluting  stents  (DES),  for  example,  are  not
implanted  due  to  a  hypothetical  higher  risk  of  device-
related  complications  (i.e.  stent  thrombosis  or  bleeding
in  the  case  of  premature  withdrawal  or  prolonged  dual
antiplatelet  therapy,  respectively).  Nevertheless,  elderly
patients  are  potentially  those  who  could  beneﬁt  the  most
from  the  use  of  DES  considering  the  high  prevalence  of
lesion  characteristics  that  increase  the  restenosis  risk,
such  as  multivessel  and  small  coronary  artery  disease
[7,8].
w
t
sWe  recently  demonstrated,  in  an  all-comer  patient  pop-
lation,  that  DES  of  small  vessel  disease  is  associated  with
 signiﬁcant  reduction  in  target  vessel  revascularization
TVR)  compared  with  bare-metal  stenting  [9].  This  beneﬁcial
ffect  of  DES  was  persistent  at  long-term  follow-up  and  did
ot  increase  the  risk  of  myocardial  infarction,  stent  throm-
osis  or  bleeding.  Of  interest,  a  low  TVR  rate  of  17%  was
oted  with  the  latest  generation  thin-strut  chrome-cobalt
MS.  Therefore,  their  use  could  be  of  interest  in  patients
t  high  risk  of  bleeding  with  prolonged  dual  antiplatelet
herapy,  such  as  elderly  patients.  However,  few  studies  have
ssessed  the  efﬁcacy  of  DES  in  small  vessel  disease  in  elderly
atients.
The  aim  of  this  retrospective  study  was  therefore  to
ssess  the  long-term  clinical  outcome  of  elderly  patients
ith  small  vessel  disease  treated  with  DES  compared  with
he  latest  generation  thin-strut  chrome-cobalt  bare-metal
tent  (BMS).
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ethods
atient population
rom  January  2004  to  December  2008,  we  included  consecu-
ive  elderly  patients  (≥  75  years)  treated  with  PCI  and  stent
mplantation  of  native  small  coronary  vessels.  Small  vessel
isease  was  deﬁned  as  a  reference  vessel  diameter  <  3  mm
as  assessed  by  quantitative  coronary  angiography)  and/or
ize  of  the  stent  implanted  <  3  mm.  Patients  were  excluded
f:  (1)  they  were  treated  with  PCI  and  stenting  in  another
essel  >  3  mm;  (2)  PCI  was  performed  without  stent  implan-
ation;  (3)  PCI  was  performed  on  a  bypass-graft;  or  (4)
atients  received  a  DES  and  a  BMS  in  the  same  vessel.
ccording  to  the  type  of  stent  implanted,  patients  were
ivided  into  BMS  and  DES  groups.  If  a  BMS  and  a  DES  were
mplanted  in  the  same  patient,  but  in  different  coronary
rteries,  the  patient  was  assigned  to  the  DES  group.
oronary angiography and PCI
oronary  angiography  and  PCI  were  performed  at  the  physi-
ian’s  discretion  based  on  the  clinical  indication  [10]. The
tent  implanted  (i.e.  BMS  or  DES)  was  chosen  at  the  oper-
tor’s  discretion.  Quantitative  coronary  angiography  was
erformed  to  assess  stenosis  severity  using  the  computer-
ased  analysis  system  Siemens  QuantCor  QCA  (ACOM.PC
.01,  Siemens  Medical  Systems  Inc,  Malvern,  Pa).  Mini-
al  lumen  diameter  (MLD),  per  cent  diameter  stenosis,
eference  diameter,  and  lesion  length  were  measured  on
nd-diastolic  angiographic  frames.  Acute  lumen  gain  was
he  difference  between  MLD  at  the  end  of  the  inter-
ention  and  MLD  before  balloon  dilation.  Pharmacological
herapy,  including  platelet  inhibitors,  during  the  proce-
ure  and  at  discharge  was  prescribed  according  to  the
urrent  guidelines  [11].  BMS  were  Driver® Coronary  Sys-
em  (Medtronic  Vascular,  Santa  Rosa,  CA)  or  PROKinetic®
nergy  Stent  System  (BIOTRONIK  AG,  Bülach,  Switzer-
and).  DES  were  Cypher® Stent  (Cordis  J&J,  Bridgewater,
ew  Jersey),  Taxus® Stent  (Boston  Scientiﬁc  Corp.,  Nat-
ck,  Massachusetts),  Endeavor® Stent  (Medtronic  Vascular,
anta  Rosa,  CA)  and  Xience  V® Stent  (Abbott  Vascular,  CA,
SA).
ata collection and follow-up
linical  and  procedural  data  were  retrieved  from  the
atabase  of  the  Cardiovascular  Center  Aalst  OLV  Clinic,
alst  (Belgium).  Clinical  follow-up  was  carried  out  for  up
o  5  years  using  hospital  records  and  telephone  interviews.
ll  events  were  classiﬁed  and  adjudicat  ed  by  a  physician  not
nvolved  in  the  follow-up  process.  The  primary  endpoint  of
he  study  was  major  adverse  cardiac  events  (MACE),  deﬁned
s  the  composite  of  overall  death,  non-fatal  re-infarction
nd  TVR  (repeated  PCI  plus  coronary  artery  bypass  graft
urgery).  Secondary  endpoints  were  overall  death,  myocar-
ial  infarction,  TVR,  stent  thrombosis  (Academic  Research
onsortium  deﬁnitions)  and  bleeding  complications  (Throm-
olysis  in  Myocardial  Infarction  criteria)  [12—14]. This  study
omplied  with  the  Declaration  of  Helsinki  and  was  approved
y  the  local  ethical  committee.  All  patients  provided  written
nformed  consent.
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tatistical analysis
ontinuous  variables  are  expressed  as  mean  ±  standard  devi-
tion  (SD)  or  median  (interquartile  range  [IQR]).  Categorical
ariables  are  reported  as  frequencies  and  percentages.  Nor-
al  distribution  was  assessed  by  the  Kolmogorov-Smirnov
est.  Student’s  t  test  or  the  Mann-Whitney  test  was  used
o  compare  continuous  variables,  as  appropriate.  Compar-
sons  between  categorical  variables  were  evaluated  using
wo-tailed  Fisher’s  exact  test  or  Pearson’s  2 test,  as  appro-
riate.  To  adjust  for  potential  selection  bias,  a  propensity
core  was  built  with  a  non-parsimonious  method  by  the
eans  of  a  logistic  regression  model  relating  stent  group
DES  vs.  BMS)  to  pretreatment  patient  characteristics  [15].
peciﬁcally,  all  the  variables  listed  in  Table  1  and  the  base-
ine  angiographic  characteristics  included  in  Table  2  were
ncorporated  into  the  model  and  the  score  was  then  used  in
roportional  hazards  analyses  as  a  covariate.  Survival  was
valuated  by  the  Kaplan−Meier  method  and  Cox  propor-
ional  hazard  analysis.  A  P  value  of  <  0.05  was  considered
tatistically  signiﬁcant.  All  analyses  were  performed  with
PSS  version  16  (SPSS  Inc,  Chicago,  Ill).
esults
aseline clinical data
ver  the  inclusion  period,  293  elderly  patients  (≥  75  years)
ith  small  vessel  disease  undergoing  PCI  fulﬁlled  the  inclu-
ion  criteria  and  were  included  in  the  registry:  175  were
reated  with  BMS  and  118  with  DES.  Baseline  clinical  charac-
eristics  are  summarized  in  Table  1. Patients  included  in  the
ES  group  were  younger  (81  ±  4  vs.  82  ±  4;  P  = 0.007),  more
ikely  to  have  diabetes  mellitus  (62%  vs.  9%;  P  <  0.0001),  had
 higher  body  mass  index  (27  ±  4  vs.  26  ±  4;  P  =  0.02)  and
ere  more  likely  to  have  had  a  previous  PCI  (45%  vs.  31%;
 = 0.01)  than  those  in  the  BMS  group.
ngiographic and procedural data
ngiographic  and  procedural  characteristics  are  presented
n  Table  2.  Multivessel  PCI,  number  of  vessels  treated  and
ean  stents  implanted  per  patient  were  not  signiﬁcantly
ifferent  between  the  two  groups.  The  rates  of  DES  and  BMS
ere  similar  in  all  three  coronary  arteries.  Reference  vessel
iameter,  MLD  and  stent  diameter  did  not  differ  signiﬁcantly
etween  the  BMS  and  DES  groups.  However,  lesion  length
nd  stent  length  were  signiﬁcantly  higher  in  the  DES  group.
 trend  toward  higher  acute  lumen  gain  was  observed  in
ES  group.  The  rate  of  peri-procedural  myocardial  infarction
id  not  differ  between  groups  (12  [7%]  vs.  5  [4%];  P  =  0.35).
he  zotarolimus-eluting  (Endeavor)  stent  was  the  most  fre-
uently  implanted  type  of  DES.
linical follow-up
linical  follow-up  was  obtained  in  282  of  293  (96%)  patients.
he  median  (IQR)  follow-up  was  3.5  (2.4)  years.  Unadjusted
nd  propensity  score-adjusted  analysis  results  are  shown  in
able  3;  Kaplan−Meier  curves  are  shown  in  Fig.  1. There
as  no  signiﬁcant  difference  in  mortality  and  non-fatal
DES  vs.  BMS  in  elderly  patients  557
Table  1  Baseline  clinical  characteristics.
BMS(n =  175)  DES(n =  118)  p
Men  96  (55)  68  (58)  0.64
Age  (years)  82  ±  4  81  ±  4  0.007
Body  mass  index  (kg/m2)  26  ±  4  27  ±  4  0.02
Ejection  fraction  (%)  63  ±  17  62  ±  19  0.47
Family  history  of  CAD  40  (23)  30  (25)  0.61
Previous  PCI 54  (31) 53 (45) 0.01
Previous  CABG 24  (14) 21 (18) 0.34
CVD  16  (9) 13 (11) 0.60
PVD  22  (13)  16  (14)  0.81
Smoking  59  (34)  50  (42)  0.13
Diabetes  mellitus  16  (9)  73  (62)  <  0.0001
Hypertension  121  (69)  87  (74)  0.40
Hyperlipidaemia  105  (60)  75  (64)  0.54
Clinical  presentation
Stable  angina  115  (66)  76  (64)  0.82
UA/NSTEMI  35  (20)  31  (26)  0.21
STEMI  25  (14)  11  (9)  0.20
Data are mean ± standard deviation or number (%).
BMS: bare-metal stent; CABG: coronary artery bypass graft; CAD: coronary artery disease in ﬁrst-degree relative; CVD: cerebrovascular
disease; DES: drug-eluting stent; NSTEMI: non ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention;
PVD: peripheral vascular disease; STEMI: ST-segment elevation myocardial infarction; UA: unstable angina.
Table  2  Baseline  angiographic  and  procedural  characteristics.
BMS(n =  175)  DES(n =  118)  p
Multivessel  PCI  11  (6)  14  (12)  0.09
Number  of  vessels  treated  1.1  ±  0.3  1.1  ±  0.3  0.16
Stents  implanted/patient  1.3  ±  0.6  1.4  ±  0.6  0.41
Coronary  artery  stenteda
Left  anterior  descending 82  (44)  69  (52)  0.14
Left  circumﬂex 72  (39) 45  (34)  0.42
Right  coronary  artery 33  (18)  18  (14)  0.34
Diameter  stenosis  (%) 72.0  ±  14.3 73.2  ±  13.1  0.45
RVD  (mm)  2.3  ±  0.3  2.2  ±  0.4  0.20
MLD  (mm)  0.8  ±  0.3  0.7  ±  0.3  0.07
Lesion  length  (mm) 13.7  ±  7.5  17.1  ±  7.9  0.02
Stent  diameter  (mm)  2.6  ±  0.2  2.6  ±  0.1  0.88
Stent  length  (mm)  21.8  ±  11.8  26.9  ±  14.8  <  0.001
Acute  lumen  gain  (mm)  1.4  ±  0.5  1.5  ±  0.5  0.12
Type  of  DESb —  —
ZES  —  62  (41)  —
PES  —  46  (30)  —
EES  —  26  (17)  —
SES  —  17  (11)  —
Other  —  1  (1)  —
Data are mean ± standard deviation or number (%).
BMS: bare-metal stent; DES: drug-eluting stent; RVD: reference vessel diameter; MLD: minimal lumen diameter; ZES: zotarolimus-eluting
stent; SES: sirolimus-eluting stent; EES: everolimus-eluting stent; PES: paclitaxel-eluting stent.
a 187 and 132 arteries were implanted with BMS and DES, respectively.
b 152 DES were implanted.
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Table  3  Clinical  events.
Endpoint  Unadjusted  Propensity  score  adjusted
BMS
(n  =  175)
DES
(n  =  107)
HR  (95%  CI)  for
DES  vs  BMS
p  HR  (95%  CI)  for
DES  vs  BMS
p  HR  (95%  CI)  for
propensity  score
p
Death  30  (17)  18  (17)  1.01  (0.56—1.81)  0.97  0.78  (0.38—1.64)  0.52  1.12  (0.92—1.39)  0.26
Non-fatal  MI17  (10)  11  (10)  0.96  (0.44—2.10)  0.93  0.80  (0.30—2.14)  0.66  1.09  (0.83—1.43)  0.53
TVR  34  (19)  11  (10)  0.50  (0.25—0.98)  0.044  0.33  (0.14—0.76)  0.009  1.21  (0.98—1.50)  0.81
MACE  68  (39)  26  (24)  0.61  (0.39—0.96)  0.033  0.42  (0.24—0.72)  0.002  1.20  (1.03—1.38)  0.014
BMS
(n  =  175)
DES
(n  =  107)
HR  (95%  CI)  p
Death
Unadjusted
DES  30  (17)  18  (17)  1.01  (0.56—1.81)  0.97
Propensity  score  adjusted
DES  0.78  (0.38—1.64)  0.52
Propensity  score  1.12  (0.92—1.39)  0.26
Non-fatal  myocardial  infarction
Unadjusted
DES  17  (10)  11  (10)  0.96  (0.44—2.10)  0.93
Propensity  score  adjusted
DES  0.80  (0.30—2.14)  0.66
Propensity  score 1.09  (0.83—1.43)  0.53
Target  vessel  revascularization
Unadjusted
DES  34  (19) 11  (10)  0.50  (0.25—0.98)  0.044
Propensity  score  adjusted
DES  0.33  (0.14—0.76) 0.009
Propensity  score 1.21  (0.98—1.50) 0.81
Major  adverse  cardiac  events
Unadjusted
DES  68  (39) 26  (24) 0.61  (0.39—0.96) 0.033
Propensity  score  adjusted
DES  0.42  (0.24—0.72)  0.002
Propensity  score  1.20  (1.03—1.38)  0.014
BMS: bare-metal stent; CI: conﬁdence interval; DES: drug-eluting stent; HR: hazard ratio; MACE, major adverse cardiac events; MI:
myocardial infarction; TVR: target vessel revascularization.
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cyocardial  infarction  between  groups.  However,  rates
f  TVR  and  MACE  were  lower  in  the  DES  group  in  both
nadjusted  and  adjusted  analyses.  The  incidence  of  stent
hrombosis  was  similar  in  both  groups  (two  patients  in  each
roup).  There  was  no  signiﬁcant  difference  in  bleeding
omplications  and  only  a  trend  towards  more  transfusions
3  [2%]  vs.  0;  P  =  0.08)  in  the  BMS  group.
iscussion
he  present  retrospective  study  suggests  that  DES  are  safe
nd  more  effective  than  the  latest-generation  BMS  in  reduc-
ng  TVR  and  MACE  at  long-term  follow-up  in  elderly  patients
ith  small  vessel  disease.  The  number  of  elderly  patients
eferred  to  PCI  is  increasing  rapidly  [1—3].  Age  is  a major
eterminant  of  clinical  outcomes  in  patients  with  coronary
rtery  disease  [1—6],  and  elderly  patients  are  considered  at
igher  risk  of  ischaemic  and  bleeding  complications.  These
[
s
o
Dactors,  frailty  and  a higher  rate  of  comorbidities  [1—3]
eads  to  suboptimal  treatment  of  elderly  patients  [4—6]:
hey  are,  for  example,  often  denied  novel  and  more  effec-
ive  technologies,  as  suggested  by  their  exclusion  or  low  rate
f  inclusion  in  randomized  clinical  trials  [16].
Elderly  patients  often  present  with  multivessel  and  small
oronary  artery  disease  (58—69%)  [1—3].  These  anatomical
haracteristics  are  predictive  of  restenosis,  which  can  be
revented  by  the  use  of  DES  [7,8,17]. Nevertheless,  scarce
ata  on  long-term  safety  and  efﬁcacy  of  DES  are  available
n  elderly  patients.  Two  single-centre  observational  studies
ave  reported  that  DES  in  elderly  patients  are  as  safe  as  BMS
18,19].  Recently,  in  the  largest  series  of  elderly  patients
reated  with  PCI,  Wang  et  al.  reported  that  DES  were  asso-
iated  with  a  superior  long-term  clinical  beneﬁt  than  BMS
3].  None  of  these  studies  speciﬁcally  focused  on  small  ves-
el  disease,  nor  did  they  demonstrate  a  signiﬁcant  reduction
f  repeat  revascularization  in  elderly  patients  treated  with
ES.  The  lack  of  anti-restenotic  effect  of  DES  was  partly
DES  vs.  BMS  in  elderly  patients  559
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stent; DES: drug-eluting stent; MACE: major adverse cardiac events
attributed  to  the  lower  use  of  revascularization  in  elderly
patients,  which  may  lead  to  underestimation  of  the  ben-
eﬁt  of  DES  on  repeat  revascularization.  Alternatively,  this
could  also  be  due  to  the  improved  performance  of  latest
generation  thin-strut  chrome-cobalt  BMS.
We  recently  reported  a  low  (17%)  TVR  rate  in  all-comer
patients  with  small  vessel  disease  treated  with  contempo-
rary  BMS  [9].  These  data  were  also  replicated  in  the  current
study  conducted  in  elderly  patients  with  small  vessel  disease
where  we  observed  a  19%  TVR  rate  with  BMS.  In  addition,  we
conﬁrmed  that  the  clinical  beneﬁt  of  DES  in  elderly  patients
with  small  vessel  disease  is  mostly  driven  by  a  reduction
in  TVR.  This  favourable  outcome  was  obtained  despite  the
higher  incidence  of  diabetes  in  the  DES  group.  This  uneven
treatment  allocation  is  mainly  explained  by  the  Belgian
reimbursement  policy  at  the  time  of  the  study  recruitment
that  restricted  reimbursement  of  DES  to  diabetic  patients.
To  account  for  this  heterogeneity,  we  performed  propensity
score-adjusted  analyses  that  conﬁrmed  a  67%  TVR  reduction
(
c
sI (B), TVR (C) and MACE (D) at 5-year follow-up. BMS: bare-metal
 myocardial infarction; TVR: target vessel revascularization.
nd  a  58%  reduction  of  MACE  with  DES.  Finally,  the  safety
roﬁle  of  DES  was  similar  to  that  of  BMS  with  no  difference
n  bleeding,  need  for  blood  transfusion,  peri-procedural
yocardial  infarction  or  stent  thrombosis.
Currently,  the  main  limitation  of  DES  in  elderly  patients
s  the  need  for  prolonged  dual  antiplatelet  therapy  (DAPT),
specially  in  patients  at  high  risk  of  bleeding.  However,
ecent  data  suggests  that  a  shorter  period  of  DAPT  with
ES  may  be  sufﬁcient.  A  randomized  clinical  trial  between
 drug-coated  stent  and  BMS  (Leaders  Free,  NCT01623180)
hat  is  assessing  the  potential  for  delivering  the  anti-
estenotic  beneﬁt  of  a  DES  with  a  shorter  course  of  DAPT
n  patients  at  high  risk  of  bleeding  will  provide  important
nformation.  This  ongoing  study  could  potentially  change
ur  clinical  practice  by  facilitating  a  short  DAPT  duration
1  month)  in  patients  who  may  not  be  suitable  for  longer
ourses  of  treatment.
As  in  all  retrospective  observational  investigations,  our
tudy  is  limited  by  its  non-randomized  nature.  Also,  the
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eﬁnition  of  elderly  in  our  study  was  age  ≥  75  years,  while
ther  studies  have  chosen  a  higher  limit,  e.g.  80  years.  Our
ower  age  limit  could  have  reduced  our  event  rates,  but
espite  including  a  wider  range  of  ages,  the  size  of  our
opulation  is  relatively  small.  In  addition,  the  reasons  for
hoosing  a  DES  or  BMS  were  at  the  operator’s  discretion
nd  were  not  gathered  prospectively.  We  noted  differences
n  clinical  and  procedural  characteristics  between  groups.
owever,  our  ﬁndings  reﬂect  clinical  practice.  To  minimize
or  potential  bias  due  to  uncontrolled  treatment  allocation,
e  performed  a  propensity  score  adjusted  analysis.  Of  note,
ES  were  still  associated  with  improved  outcome  despite
ore  unfavourable  clinical  and  procedural  characteristics.
Another  limitation  of  our  study  is  the  possible  under-
eporting  of  some  events  (i.e.  minor  bleedings)  at  clinical
ollow-up.  Compliance  to  DAPT  after  PCI  might  potentially
nﬂuence  long-term  bleeding  risk  in  these  elderly  patients.
t  1  year,  35  (20%)  patients  in  the  BMS  group  and  80  (75%)
atients  in  the  DES  groups  (P  <  0.001)  were  taking  DAPT.
nfortunately,  we  did  not  collect  this  information  at  the
atest  clinical  follow-up.  However,  taking  into  account  the
bove-mentioned  under-reporting  issue,  we  did  not  observe
ny  signiﬁcant  difference  between  the  two  groups  in  terms
f  bleeding.
The  deﬁnition  of  small  vessel  disease  varies  from  study
o  study  and  is  based  primarily  on  the  pre-PCI  angiographic
stimation  of  reference  vessel  diameter  (<  2.8  to  3.0  mm)
20—22].  Other  studies  have  chosen  to  deﬁne  vessels  as
mall  if  the  stent  diameter  was  <  3.0  mm  [23].  Although
e  acknowledge  the  limitation  of  a  classiﬁcation  based
xclusively  on  angiographic  data,  we  minimized  potential
isclassiﬁcation  by  including  only  vessels  with  a  reference
essel  diameter  and  a  stent  size  <  3  mm.
onclusions
n  elderly  patients,  PCI  of  small  vessel  disease  represents
 challenge  for  interventional  cardiologists.  In  this  retro-
pective,  non-randomized  analysis  on  the  treatment  of  small
essel  disease  in  elderly  patients,  DES  were  as  safe  as  and
ore  effective  than  BMS,  with  a  signiﬁcant  reduction  in  the
ate  of  TVR.
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